Company: NIVFW
Filing Date: 2025-05-01
Form Type: F-1/A
Source: 0001213900-25-038045
Chunk: 174

Company: NewGenIvf Group Ltd
Filing Date: 2025-05-01
Form: F-1/A
Chunk 174
---
 purchase price of $365,250. Between January 21, 2025 to January 23, 2025, the Company issued 4,000,000 Class A Ordinary Shares (equivalent to 200,000 Class A Ordinary Shares post Reverse Stock Split) for a purchase price of $1,181,898. On February 3, 2025, the Company issued 2,000,000 Class A Ordinary Shares (equivalent to 100,000 Class A Ordinary Shares post Reverse Stock Split) for a purchase price of $280,000. On February 7, 2025, the Company issued 4,000,000 Class A Ordinary Shares (equivalent to 200,000 Class A Ordinary Shares post Reverse Stock Split) for a purchase price of $431,068. On February 10, 2025, the Company issued 7,000,000 Class A Ordinary Shares (equivalent to 350,000 Class A Ordinary Shares post Reverse Stock Split) for a purchase price of $802,821. On February 20, 2025, the Company issued 125,000 Class A Ordinary Shares (on a post-Reverse Stock Split basis) for a purchase price of $261,822. On February 28, 2025, the Company issued 100,000 Class A Ordinary Shares (on a post-Reverse Stock Split basis) for a purchase price of $190,120. On March 3, 2025, the Company issued 25,000 Class A Ordinary Shares (on a post-Reverse Stock Split basis) for a purchase price of $34,678. On April 3, 2025, the Company issued 325,000 Class A Ordinary Shares (on a post-Reverse Stock Split basis) for a purchase price of $302,240. The Company received gross proceeds of $7,129,921 and issued an aggregate of 1,930,000 Class A Ordinary Shares (on a post-Reverse Stock Split basis) to White Lion. MicroSort Acquisition On January 21, 2025, the Company entered into a Purchase Agreement with Genetics & IVF Institute, Inc. (“Purchase Agreement”), pursuant to which the Company purchased all of the Assets (as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort Business (as defined in the Purchase Agreement) from Genetics & IVF Institute, Inc. for a cash consideration of $750,000 and a share